2. Apoptosis
  3. Caspase Apoptosis
  4. Raptinal

Raptinal, a agent that directly activates caspase-3, initiates intrinsic pathway caspase-dependent apoptosis. Raptinal is able to rapidly induce cancer cell death by directly activating the effector caspase-3, bypassing the activation of initiator caspase-8 and caspase-9.

For research use only. We do not sell to patients.

CAS No. : 1176-09-6

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Raptinal Related Antibodies

Top Publications Citing Use of Products

    Raptinal purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2025 Nov:393:115371.  [Abstract]

    Raptinal (20 mg/kg; i.p. 30 min before modeling) reverses the favorable effects of AAV9-shKIF23 on the memory ability of PND mice.

    Raptinal purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2025 Nov:393:115371.  [Abstract]

    Gel images of KIF23, caspase-3, cleaved caspase-3, GSDME, and N-GSDME in the hippocampus following the Raptinal (20 mg/kg; i.p. 30 min before modeling) treatments.

    Raptinal purchased from MedChemExpress. Usage Cited in: Part Fibre Toxicol. 2024 Mar 7;21(1):13.  [Abstract]

    Cell viability of trophoblast cells treated with 10 μM Raptinal, 15 μM Quinacrine dihydrochloride, or 500 μg/mL PS-NPs, and co-treated with 10 μM Z-VAD-FMK for 48 h.

    Raptinal purchased from MedChemExpress. Usage Cited in: Cell Syst. 2024 Jul 1:S2405-4712(24)00176-5.  [Abstract]

    Annexin V staining assays to quantify the number of apoptotic cells following expression of mARG vectors. HEK293T cells transfected with pgvpA-IRES-mCherry with the start codon removed in front of gvpA were used to establish a baseline (Not Treated). A subset of these cells was treated with Raptinal (10 μM; 18 h) to induce apoptosis (Raptinal Treated). Other cell populations were transfected solely with a fully functional pgvpA-IRES-mCherry (gvpA-IRES-mCherry), the two-vector system (Two-vector), or the ACC/ACC SEMPER mARG plasmid (SEMPER mARG).

    Raptinal purchased from MedChemExpress. Usage Cited in: Front Immunol. 2023 Nov 23;14:1282710.  [Abstract]

    Vδ2 T cells induce pyroptosis in mesothelioma cells. Analysis of protein expression level of gasdermin (Gas)E, caspase 3, GasD, caspase 4, and IL-18, following 6 h of co-culture between Vδ2 T cells and MSTO-luc. Controls include Raptinal (10 μM; 6 h) and terfenadine, or cells only.

    View All Caspase Isoform Specific Products:

    View All Isoforms
    Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Raptinal, a agent that directly activates caspase-3, initiates intrinsic pathway caspase-dependent apoptosis. Raptinal is able to rapidly induce cancer cell death by directly activating the effector caspase-3, bypassing the activation of initiator caspase-8 and caspase-9[1][2].

    IC50 & Target[1]

    Caspase 3

     

    In Vitro

    H. pylori infection-induced apoptosis resistance in gastric epithelial cells triggered by Raptinal[1].
    Treatment with 10 μM of Raptinal for 2 h induces the cleavage of pro-caspase-3 into it’s active form in human gastric cancer cell lines AGS, MKN28, MKN45[1].
    Raptinal initiates intrinsic pathway caspase-dependent apoptosis within minutes in multiple cell lines. Raptinal induces death against various cancer and non-cancerous cell lines with 24 hour IC50 values between 0.7-3.4 μM, indicating activity across a wide variety of cell lines[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Raptinal Related Antibodies

    Cell Viability Assay[2]

    Cell Line: Human Lymphoma U-937, SKW 6.4, or Jurkat cell lines
    Concentration: 0.7-3.4 μM
    Incubation Time: 24 hours
    Result: The IC50 values of Raptinal against U-937, SKW 6.4, or Jurkat cell lines were 1.1±0.1, 0.7±0.3, 2.7±0.9 μM, respectively.

    Western Blot Analysis[1]

    Cell Line: Human gastric cancer cell lines AGS, MKN28, MKN45
    Concentration: 10 μM
    Incubation Time: 2 hours
    Result: Induced apoptosis by activating caspase-3 within 30 min at a concentration of 10 μM.
    Treatment with 10 μM of Raptinal for 2 h induced the cleavage of pro-caspase-3 into it’s active form in all three cell lines. 
    In Vivo

    Raptinal is an unusually rapid inducer of caspase-dependent apoptosis in multiple cell lines and in vivo systems[1].
    Raptinal (20 mg/kg; administered intraperitoneally; once daily for 3 consecutive days for B16-F10 and 4 consecutive days for 4T1 models) exerts anticancer activity in vivo[2].
    C57BL/6 mice are administered intravenous Raptinal across a range of dosages as a one-time injection. When administered intravenously at a dosage of 37.5 mg/kg, the peak plasma concentration and elimination half-life of Raptinal are 54.4±0.9 μg/mL and 92.1±5.8 minutes, respectively. Single-dose intravenous Raptinal is well tolerated across a wide dose range (15-60 mg/kg) and does not cause hematologic toxicity as assessed 7 days post-administration[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: C57BL/6 and BALB/c female mice (6-8 weeks old) bearing the B16-F10 model or 4T1 models[2]
    Dosage: 20 mg/kg
    Administration: Administered intraperitoneally; once daily for 3 consecutive days for B16-F10 and 4 consecutive days for 4T1 models
    Result: Retard tumor volume and tumor mass by 60% relative to controls in the B16-F10 model.
    Similar efficacy was observed for the 4T1 murine breast cancer tumor model with 50% growth inhibition after treatment. 
    Molecular Weight

    386.44

    Formula

    C28H18O2
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=CC1(C2(C=O)C3=C(C4=C2C=CC=C4)C=CC=C3)C5=C(C6=C1C=CC=C6)C=CC=C5
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 20 mg/mL (51.75 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5877 mL 12.9386 mL 25.8772 mL
    5 mM 0.5175 mL 2.5877 mL 5.1754 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.54%

    SDS (393 KB)

    COA (274 KB) HNMR (452 KB) LCMS (102 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.5877 mL 12.9386 mL 25.8772 mL 64.6931 mL
    5 mM 0.5175 mL 2.5877 mL 5.1754 mL 12.9386 mL
    10 mM 0.2588 mL 1.2939 mL 2.5877 mL 6.4693 mL
    15 mM 0.1725 mL 0.8626 mL 1.7251 mL 4.3129 mL
    20 mM 0.1294 mL 0.6469 mL 1.2939 mL 3.2347 mL
    25 mM 0.1035 mL 0.5175 mL 1.0351 mL 2.5877 mL
    30 mM 0.0863 mL 0.4313 mL 0.8626 mL 2.1564 mL
    40 mM 0.0647 mL 0.3235 mL 0.6469 mL 1.6173 mL
    50 mM 0.0518 mL 0.2588 mL 0.5175 mL 1.2939 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Raptinal Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Raptinal1176-09-6CaspaseApoptosisDirectlyactivatescaspase-3intrinsicpathwaycaspase-dependentapoptosisInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Raptinal
    Cat. No.:
    HY-121320
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.